US Bancorp’s Trinity Biotech TRIB Stock Holding History

US Bancorp’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6	Closed	-$417	–	4100
2023 Q4	$417	Hold	6	–	–	﹤0.01%	3863
2023 Q3	$715	Hold	6	–	–	﹤0.01%	3817
2023 Q2	$924	Hold	6	–	–	﹤0.01%	3815
2023 Q1	$914	Hold	6	–	–	﹤0.01%	3891
2022 Q4	$962	Hold	6	–	–	﹤0.01%	3930
2022 Q3	$1K	Hold	6	–	–	﹤0.01%	4011
2022 Q2	$1K	Sell	6 -1	-14%	-$183	﹤0.01%	4009
2022 Q1	$1K	Hold	7	–	–	﹤0.01%	4002
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	4034
2021 Q3	$2K	Hold	7	–	–	﹤0.01%	3922
2021 Q2	$3K	Hold	7	–	–	﹤0.01%	3763
2021 Q1	$4K	Hold	7	–	–	﹤0.01%	3566
2020 Q4	$4K	Sell	7 -1	-13%	-$496	﹤0.01%	3462
2020 Q3	$2K	Hold	8	–	–	﹤0.01%	3524
2020 Q2	$3K	Hold	8	–	–	﹤0.01%	3451
2020 Q1	$1K	Hold	8	–	–	﹤0.01%	3610
2019 Q4	$1K	Hold	8	–	–	﹤0.01%	3594
2019 Q3	$1K	Sell	8 -6	-43%	-$1.56K	﹤0.01%	3520
2019 Q2	$3K	Sell	14 -28	-67%	-$9.99K	﹤0.01%	3404
2019 Q1	$18K	Sell	42 -27	-39%	-$11.1K	﹤0.01%	2901
2018 Q4	$24K	Hold	69	–	–	﹤0.01%	2746
2018 Q3	$41K	Sell	69 -10	-13%	-$6.52K	﹤0.01%	2657
2018 Q2	$59K	Sell	79 -60	-43%	-$43.3K	﹤0.01%	2496
2018 Q1	$108K	Sell	139 -108	-44%	-$88.4K	﹤0.01%	2195
2017 Q4	$189K	Sell	247 -216	-47%	-$167K	﹤0.01%	1917
2017 Q3	$390K	Sell	463 -304	-40%	-$254K	﹤0.01%	1535
2017 Q2	$690K	Sell	767 -1,581	-67%	-$1.34M	﹤0.01%	1252
2017 Q1	$2.1M	Buy	2,348 +70	+3%	+$65.7K	0.01%	761
2016 Q4	$2.37M	Buy	2,278 +5	+0.2%	+$5.17K	0.01%	695
2016 Q3	$4.51M	Sell	2,273 -61	-3%	-$114K	0.02%	486
2016 Q2	$3.97M	Buy	2,334 +166	+8%	+$281K	0.02%	498
2016 Q1	$3.79M	Buy	2,168 +576	+36%	+$917K	0.01%	503
2015 Q4	$2.81M	Buy	1,592 +808	+103%	+$1.43M	0.01%	600
2015 Q3	$1.34M	Buy	784 +308	+65%	+$743K	0.01%	824
2015 Q2	$1.29M	Buy	476 +123	+35%	+$319K	0.01%	893
2015 Q1	$1.02M	Buy	353 +51	+17%	+$141K	﹤0.01%	1007
2014 Q4	$794K	Sell	302 -89	-23%	-$230K	﹤0.01%	1107
2014 Q3	$1.07M	Sell	391 -176	-31%	-$572K	﹤0.01%	961
2014 Q2	$1.96M	Buy	567 +20	+4%	+$71.1K	0.01%	716
2014 Q1	$1.99M	Buy	547 +161	+42%	+$633K	0.01%	695
2013 Q4	$1.46M	Buy	386 +139	+56%	+$501K	0.01%	769
2013 Q3	$807K	Buy	247 +117	+90%	+$342K	﹤0.01%	988
2013 Q2	$329K	Buy	+130	New	+$323K	﹤0.01%	1391

Other funds holding TRIB

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

BCM

Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

US Bancorp's TRIB Position: Q1 2024 in Review

US Bancorp sold out of Trinity Biotech (TRIB) in Q1 2024, closing a stake of 6 shares — an estimated $417 sold.

US Bancorp first reported a position in TRIB in Q2 2013 and held it in 43 quarters. The position peaked at $4.51M in Q3 2016. 19 funds tracked by Wall St. Rank hold TRIB as of Q1 2024.

US Bancorp reported no remaining Trinity Biotech position as of Q1 2024 after selling out during the quarter.
US Bancorp sold 6 Trinity Biotech shares in Q1 2024, an estimated $417.
US Bancorp first reported a position in Trinity Biotech in Q2 2013 and held it in 43 quarters.
US Bancorp's Trinity Biotech position peaked at $4.51M in Q3 2016.
19 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.